THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES

BACKGROUND: BRAF mutations occur in 50% of melanoma patients. Targeted agents – BRAF and MEK inhibitors and immunotherapy improve survival of melanoma patients with BRAF mutations. These agents have intracranial efficacy as shown in clinical trials. However, the efficacy of immunotherapies (immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauko, Adam, Sagar, Soumya, Barnett, Addison, Wei, Wei, Chao, Samuel, Stevens, Glen, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213464/
http://dx.doi.org/10.1093/noajnl/vdz014.053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213464/
http://dx.doi.org/10.1093/noajnl/vdz014.053

Ejemplares similares